The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
Latest news from ARC
14 years strong: Northern California patient support group
On October 20th the Northern California Amyloidosis Support Group celebrated it’s fourteenth year with a meeting held at Stanford’s Blake Wilbur Cancer Center.
Tegsedi (Inotersen) approved by FDA for hATTR amyloidosis
The U.S. Food and Drug Administration today approved Tegsedi (inotersen), a novel therapy for the treatment of hereditary TTR amyloidosis polyneuropathy.